Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04943432 · ClinicalTrials.gov registry record · NA
Open Trial of a Behavioral Activation Telepsychology Intervention for People Who Inject Drugs
A NA study of Intravenous Drug Usage, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT04943432: Completed NA study of Intravenous Drug Usage, sponsored by University of North Carolina, Chapel Hill.
NCT04943432 is a NA study of Intravenous Drug Usage that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 23 participants, below the 519-participant average among 3 other Intravenous Drug Usage trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04943432, a NA study of Intravenous Drug Usage, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The study has two aims: 1) To examine the feasibility and acceptability of administering a telepsychology Behavioral Activation (BA) treatment for substance use among non-treatment-seeking people who inject drugs (PWID); 2) To test the initial efficacy of the treatment from pretreatment to a 1-month follow-up on substance-related problems, readiness to change drug use, and BA. The intervention is hypothesized to be feasible and well-accepted, and within-subject analyses are hypothesized to demonstrate decreases in substance-related problems and increases in readiness to change drug use and BA from pretreatment to a 1-month follow-up. The study aims to recruit N=25 non-treatment-seeking PWID from a syringe exchange program (estimated treated sample n=15). Participants will receive 8 sessions of BA over 4 weeks, and assessment of study outcome measures will occur at pretreatment, post-treatment, and a one-month follow-up.
Primary Outcome
Behavioral Activation for Depression Scale (BADS) total score; Scale range 0-150, higher scores indicate greater activation (positive outcome).
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Activation
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2022-05-08 |
| Phase | NA |
What the finished NCT04943432 record still lists
NCT04943432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 519-participant average among 3 other Intravenous Drug Usage trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Intravenous Drug Usage appearing as the primary indexed condition, and to 1 intervention - of which Behavioral Activation is the first listed.
NCT04943432 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04943432 about?
NCT04943432 is a clinical study titled "Open Trial of a Behavioral Activation Telepsychology Intervention for People Who Inject Drugs". The study has two aims: 1) To examine the feasibility and acceptability of administering a telepsychology Behavioral Activation (BA) treatment for substance use among non-treatment-seeking people who inject drugs (PWID); 2) To test the initial efficacy of the treatment from pretreatment to a 1-month...
What is the current status of trial NCT04943432?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2021-09-29. Estimated completion is 2022-05-08.
What conditions does trial NCT04943432 study?
This clinical trial studies the following conditions: Intravenous Drug Usage.
What interventions are being tested in trial NCT04943432?
The interventions under investigation include: Behavioral Activation (BEHAVIORAL).
Who is sponsoring clinical trial NCT04943432?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04943432 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intravenous Drug Usage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI